Star Exports

Star Exports is a globally recognized trading and wholesale company based in Mumbai, India, with over 32 years of experience in the export industry. Established in 1990, the company specializes in exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, as well as toiletries, cosmetics, and fast-moving consumer goods (FMCG). Their portfolio features renowned Indian brands such as Dettol, Iodex, and Burnol.

The company operates under the ownership of Mr. Samir Rokadia, who serves as the Proprietor. Star Exports is registered with the Directorate General of Foreign Trade (DGFT), reflecting its compliance with Indian export regulations. While specific financial details are not publicly disclosed, the company has achieved a total export value of $1.3 million USD over 147 shipments from 2022 to 2026. The workforce comprises approximately 11 to 50 employees, indicating a medium-sized enterprise.

Star Exports operates manufacturing facilities in Mumbai, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding plant capacities and specialized manufacturing processes are not publicly disclosed. However, the company's extensive experience and export volume suggest a well-established manufacturing infrastructure capable of meeting international standards.

The leadership of Star Exports is headed by Mr. Samir Rokadia, who serves as the Proprietor. Specific details regarding other key executives, such as the CEO, CFO, and other senior management roles, are not publicly available. The company's leadership is known for its commitment to quality and customer satisfaction, as evidenced by their adherence to ethical practices and social responsibility.

Star Exports has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports finished pharmaceutical formulations, such as Dettol, Iodex, and Burnol, which are recognized and approved in these regions. While specific regulatory filings and approvals are not publicly disclosed, the company's adherence to international quality standards and ethical practices suggests compliance with the regulatory requirements of these markets.

Star Exports has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's products, including Dettol, Iodex, and Burnol, are recognized and approved in these regions. While specific details regarding WHO prequalification are not publicly available, the company's commitment to quality and ethical practices indicates a focus on meeting international standards to facilitate market access.

Star Exports demonstrates a diversified geographic strategy by exporting to both regulated markets and emerging economies. This approach mitigates concentration risk and positions the company to leverage growth opportunities across different regions. The strategic direction appears to focus on expanding market reach while maintaining a strong presence in established markets.

Specific details regarding Star Exports' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's export of recognized pharmaceutical products such as Dettol, Iodex, and Burnol suggests compliance with FDA regulations. The company's adherence to international quality standards and ethical practices further indicates a commitment to meeting regulatory requirements.

While specific details regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates are not publicly available, Star Exports' export of recognized pharmaceutical products such as Dettol, Iodex, and Burnol suggests adherence to international quality standards. The company's commitment to ethical practices and social responsibility further indicates a focus on meeting global manufacturing standards.

Star Exports operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly available. However, the company's adherence to ethical practices and social responsibility suggests a commitment to meeting regulatory requirements for international trade.

As of March 2026, there are no publicly available records of FDA Form 483 observations, warning letters, or import alerts associated with Star Exports. The company's export of recognized pharmaceutical products such as Dettol, Iodex, and Burnol indicates a history of compliance with international regulatory standards. The company's commitment to quality and ethical practices further suggests a proactive approach to regulatory compliance.

In the pharmaceutical export sector, Star Exports faces competition from other Indian exporters specializing in finished pharmaceutical formulations. While specific market share data is not publicly available, the company's export value of $1.3 million USD over 147 shipments from 2022 to 2026 indicates a significant presence in the market. The company's focus on recognized brands such as Dettol, Iodex, and Burnol positions it favorably against competitors.

Star Exports' key differentiators include its extensive experience of over 32 years in the export industry, a diversified product portfolio featuring renowned Indian brands, and a commitment to quality and ethical practices. The company's adherence to international standards and social responsibility further distinguishes it in the competitive landscape.

Star Exports' current strategic direction focuses on exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, as well as FMCG products. The company's future outlook appears to involve expanding its market reach while maintaining a strong presence in established markets. The commitment to quality and ethical practices suggests a focus on sustainable growth and long-term success.

Star Exports has a track record of exporting recognized pharmaceutical products such as Dettol, Iodex, and Burnol, indicating reliability and consistency in its export operations. The company's export value of $1.3 million USD over 147 shipments from 2022 to 2026 reflects a steady volume of trade. The commitment to quality and ethical practices further enhances its reliability as a supplier.

Importers should verify the following certifications when considering Star Exports as a supplier:

• FDA Facility Registration: Confirm the registration status of Star Exports' manufacturing facilities with the U.S. Food and Drug Administration (FDA).

• WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practice (GMP) certification for the company's manufacturing facilities.

• EU GMP Certification: Ensure the company holds Good Manufacturing Practice certification recognized by the European Union.

• ISO Certification: Check for International Organization for Standardization (ISO) certifications relevant to pharmaceutical manufacturing.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Star Exports directly.

When conducting due diligence on Star Exports, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Product Quality: Request samples and review quality control processes to ensure product standards meet expectations.

• Evaluate Financial Stability: Review financial statements and export records to assess the company's financial health.

• Check References: Contact previous clients and partners to gather feedback on business practices and reliability.

• Inspect Manufacturing Facilities: If possible, conduct site visits to evaluate manufacturing capabilities and compliance with standards.

Be cautious of red flags such as inconsistent product quality, lack of transparency in operations, or negative feedback from previous partners. Recommended pre-order checks include reviewing product samples, verifying certifications, and assessing the company's financial stability.